Pepgen

Pepgen company information, Employees & Contact Information

Explore related pages

Pepgen email format Pepgen management contacts

Related company profiles:

Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological disorders.

Company Details

Employees
74
Founded
-
Address
321 Harrison Ave,
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
http://pepgen.com
Keywords
Biotechnology, Chemistry, Biology, Bioscience, Life sciences, Therapeutics.
HQ
Boston, Massachusetts
Competitors
Vertex Pharmaceuticals, Biogen, Entrada Therapeutics, Intellia Therapeutics, Inc., Wave Life Sciences, Beam Therapeutics, Kymera Therapeutics, Dyne Therapeutics, Verve Therapeutics, PepGene.
Looking for a particular Pepgen employee's phone or email?

Pepgen Questions

News

PepGen Announces Highest Mean Splicing Correction Reported in DM1 Patients - Business Wire

PepGen Announces Highest Mean Splicing Correction Reported in DM1 Patients Business Wire

FDA Pauses PepGen’s DMD Drug Trial in the US - The American Journal of Managed Care® (AJMC®)

FDA Pauses PepGen’s DMD Drug Trial in the US The American Journal of Managed Care® (AJMC®)

PepGen’s IND for Duchenne Muscular Dystrophy PMO PGN-EDO51 Placed on Clinical Hold by the FDA - CGTLive®

PepGen’s IND for Duchenne Muscular Dystrophy PMO PGN-EDO51 Placed on Clinical Hold by the FDA CGTLive®

PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference - Business Wire

PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference Business Wire

FDA Places Clinical Hold on Phase 2 Study of PGN-EDO51 in Duchenne Muscular Dystrophy - NeurologyLive

FDA Places Clinical Hold on Phase 2 Study of PGN-EDO51 in Duchenne Muscular Dystrophy NeurologyLive

PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer - Yahoo Finance

PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer Yahoo Finance

PepGen Announces Closing of $112.5 Million Crossover - GlobeNewswire

PepGen Announces Closing of $112.5 Million Crossover GlobeNewswire

PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1 - Business Wire

PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1 Business Wire

PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights - Yahoo Finance

PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights Yahoo Finance

Early Phase 1 Trial Data Suggests Therapeutic Potential for PGN-EDODM1 in Myotonic Dystrophy Type 1 - NeurologyLive

Early Phase 1 Trial Data Suggests Therapeutic Potential for PGN-EDODM1 in Myotonic Dystrophy Type 1 NeurologyLive

ASO Fast Tracked for Myotonic Dystrophy - CGTLive®

ASO Fast Tracked for Myotonic Dystrophy CGTLive®

PepGen Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights - Business Wire

PepGen Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights Business Wire

FDA Places Hold on Phase 1 Study of Exon Skipping Therapy PGN-EDODM1 in Myotonic Muscular Dystrophy - NeurologyLive

FDA Places Hold on Phase 1 Study of Exon Skipping Therapy PGN-EDODM1 in Myotonic Muscular Dystrophy NeurologyLive

FDA Lifts Clinical Hold on FREEDOM-DM1 Study of Antisense Agent PGN-EDODM1 - NeurologyLive

FDA Lifts Clinical Hold on FREEDOM-DM1 Study of Antisense Agent PGN-EDODM1 NeurologyLive

First Patient Dosed With PGN-EDODM1 in Phase 1 FREEDOM-DM1 Trial for Myotonic Dystrophy Type 1 - NeurologyLive

First Patient Dosed With PGN-EDODM1 in Phase 1 FREEDOM-DM1 Trial for Myotonic Dystrophy Type 1 NeurologyLive

PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society - Business Wire

PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society Business Wire

PepGen to Focus on Development of Promising DM1 Program Following 10 mg/kg PGN-EDO51 Update - Business Wire

PepGen to Focus on Development of Promising DM1 Program Following 10 mg/kg PGN-EDO51 Update Business Wire

PepGen Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights - Business Wire

PepGen Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights Business Wire

PepGen Appoints Noel Donnelly as Chief Financial Officer - Yahoo Finance

PepGen Appoints Noel Donnelly as Chief Financial Officer Yahoo Finance

PepGen Appoints Isami J. Salcedo Vice President of Program Management - citybiz

PepGen Appoints Isami J. Salcedo Vice President of Program Management citybiz

PepGen to Present at Stifel's 3rd Annual CNS Day - PR Newswire

PepGen to Present at Stifel's 3rd Annual CNS Day PR Newswire

PepGen (PEPG) Stock Price, News & Analysis - MarketBeat

PepGen (PEPG) Stock Price, News & Analysis MarketBeat

PepGen Appoints Afsaneh Mohebbi, Ph.D., as SVP, Portfolio and Program Management and Dave Borah, CFA, as SVP, Investor Relations and Corporate Communications - FinancialContent

PepGen Appoints Afsaneh Mohebbi, Ph.D., as SVP, Portfolio and Program Management and Dave Borah, CFA, as SVP, Investor Relations and Corporate Communications FinancialContent

FDA Action Update, December 2024: Approval, Designations, and Clinical Hold - NeurologyLive

FDA Action Update, December 2024: Approval, Designations, and Clinical Hold NeurologyLive

PEPG Stock Price and Chart — NASDAQ:PEPG - TradingView

PEPG Stock Price and Chart — NASDAQ:PEPG TradingView

RA Capital Management Leads $45M Series A Financing for - GlobeNewswire

RA Capital Management Leads $45M Series A Financing for GlobeNewswire

PepGen Announces Executive Team Promotions - FinancialContent

PepGen Announces Executive Team Promotions FinancialContent

Companies like Pepgen

PepGene logo - Similar company to Pepgen

Pepgene

NA
Entrada Therapeutics logo - Similar company to Pepgen

Entrada Therapeutics

191
Vertex Pharmaceuticals logo - Similar company to Pepgen

Vertex Pharmaceuticals

6.09K
Intellia Therapeutics, Inc. logo - Similar company to Pepgen

Intellia Therapeutic...

446
Verve Therapeutics logo - Similar company to Pepgen

Verve Therapeutics

309
Dyne Therapeutics logo - Similar company to Pepgen

Dyne Therapeutics

227
Kymera Therapeutics logo - Similar company to Pepgen

Kymera Therapeutics

250
Wave Life Sciences logo - Similar company to Pepgen

Wave Life Sciences

361
Biogen logo - Similar company to Pepgen

Biogen

7.60K
Beam Therapeutics logo - Similar company to Pepgen

Beam Therapeutics

557

Top Pepgen Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant